Wall Street is showing a growing appetite for Gossamer Bio, Inc. (NASDAQ: GOSS), as a wave of high-profile institutional buying recently shifted the biotech firm’s ownership structure. MB Generational Wealth LLC led the charge in the third quarter, reporting a substantial new position of over 1.4 million shares.
The move, valued at roughly $3.72 million, instantly made the San Diego-based biopharmaceutical company the 11th largest holding in the firm’s portfolio and signals a significant vote of confidence in the developer’s clinical-stage pipeline.
This fresh capital injection is part of a broader trend of institutional accumulation. During the first and second quarters, major players like Geode Capital Management and Goldman Sachs Group drastically increased their exposure, with Geode doubling its stake to 4.5 million shares and Goldman Sachs boosting its holdings by over 700%.
READ: The Million-Signature Sprint: Major Health Groups Join Push For Florida Medicaid Vote
Even more dramatic was the activity from Jane Street Group, which saw its position surge by more than 5,000%. With these combined moves, institutional investors and hedge funds now control a dominant 81.23% of Gossamer’s outstanding shares.
Despite the heavy-hitting support from investment firms, the stock has experienced recent volatility. Shares opened at $2.26 on Monday, reflecting a 7% decline, and remain well within a wide 12-month range of $0.76 to $3.87.
This price action comes as the company maintains a market capitalization of approximately $523 million. While the stock’s 50-day moving average sits at $2.96, the underlying financials continue to reflect the high-burn nature of clinical-stage research, evidenced by a negative price-to-earnings ratio.
Professional analysts are currently split on where the stock goes next, leading to a “Moderate Buy” consensus. The outlook is a tale of two extremes: while Weiss Ratings and Wall Street Zen have issued “Sell” warnings, other firms remain highly optimistic.
READ: CNN Data Analysis: Decline In National Pride Among Dems Reveals Deepening Partisan Rift
Barclays recently initiated coverage with an “Overweight” rating and a $9.00 price target, while HC Wainwright pushed further with a “Buy” rating and a $10.00 target.
For now, the massive influx of institutional money suggests that while the retail market may be hesitant, the pros are digging in for the long haul.
Disclosure: Neither Tampa Free Press nor the author of this article endorses any product mentioned on this page. Users should conduct their own research before taking any action related to the company. This article is not intended as financial advice. Educational purposes only.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
